Table 1 Site-level characteristics among patients with ≥ 1 visit after enrollment with CD4 ≥ 200 & WHO 1 or 2 at enrollment, MTCT-Plus Initiative, 2003-2008
Country/Site | Total | Females (%) | Median (IQR) FU time1,2 | Deaths (%) | Withdrawals3 (%) | LTF at 12mo2 (%) | LTF at 24mo2 (%) | LTF at the end of data collection2 (%) |
|---|---|---|---|---|---|---|---|---|
Cote d' Ivoire | 588 | 537 (91.3) | 1.7 (0.7-3) | 8 (1.4) | 26 (4.4) | 16 (3.5) | 32 (8) | 43 (13) |
Kisumu, Kenya | 304 | 257 (84.5) | 1.5 (0.6-2.5) | 7 (2.3) | 11 (3.6) | 58 (21.8) | 89 (35.9) | 105 (50.1) |
Thailand | 344 | 262 (76.2) | 1.8 (0.8-2.9) | 1 (0.3) | 28 (8.1) | 14 (4.9) | 50 (20.7) | 66 (33.3) |
Nsambya, Uganda | 387 | 297 (76.7) | 2.1 (1.1-3.2) | 4 (1) | 14 (3.6) | 3 (0.9) | 11 (4) | 22 (11.6) |
Zambia | 501 | 443 (88.4) | 1.4 (0.7-2.6) | 7 (1.4) | 49 (9.8) | 86 (19.5) | 130 (32.8) | 149 (45.8) |
Soweto, S.A. | 496 | 445 (89.7) | 2.7 (1–3.6) | 7 (1.4) | 39 (8.8) | 29 (6.8) | 57 (14.1) | 91 (26.2) |
Cato Manor, S.A. | 450 | 406 (90.2) | 1.2 (0.4-2.3) | 9 (2) | 140 (31.1) | 33 (10) | 44 (14.9) | 48 (19.5) |
Rwanda | 191 | 145 (75.9) | 2 (1–3.4) | 1 (0.5) | 13 (6.8) | 16 (9.5) | 28 (17.9) | 44 (39) |
Eldoret, Kenya | 286 | 244 (85.3) | 1.8 (0.4-3.5) | 1 (0.3) | 2 (0.7) | 17 (7.7) | 25 (12) | 43 (31.2) |
Mulago, Uganda | 331 | 232 (70.1) | 3.1 (1.5-3.8) | 9 (2.7) | 11 (3.3) | 1 (0.3) | 4 (1.5) | 6 (4) |
Cameroon | 400 | 345 (86.3) | 1.2 (0.6-1.8) | 4 (1) | 15 (3.8) | 16 (5.3) | 23 (8.6) | 24 (10) |
Total | 4278 | 3613 (84.5) | 1.7 (0.7-3) | 58 (1.4) | 348 (8.1) | 289 (8.2) | 493 (15.6) | 641 (26.4) |